A protein marker that helps identify melanoma early

Researchers studying PARP1 expression may have found a way to tell melanoma apart from benign skin lesions. The finding carries weight for communities with heightened UV exposure risk.

A single protein, found in elevated concentrations inside cancer cells, may help clinicians tell dangerous melanoma from harmless moles — sooner, and with greater confidence.

The Journal of Investigative Dermatology published research examining PARP1, a protein from the polyadenosine diphosphate-ribose polymerase (PARP) family, as a potential biomarker for distinguishing melanoma from benign melanocytic lesions such as nevi. PARP proteins are directly involved in genomic stability, DNA repair, and apoptosis, according to the study. They are overexpressed across a range of cancers.

In melanoma specifically, the study noted that PARP1 overexpression had previously been identified as a negative prognostic marker — one linked to more aggressive tumour biology, citing earlier work by Kupczyk et al (2021) and Mou et al (2022). The diagnostic question the new research addressed was narrower: can PARP1 expression reliably separate melanoma from benign growths at the diagnostic stage?

The study noted that this distinction had remained poorly defined in the literature, citing Staibano et al (2005) as an earlier attempt that left the question open.

Why early detection matters here

Early melanoma detection is associated with excellent survival outcomes, according to Patel et al (2023), also cited in the research. That connection between timing and outcome underpins the entire value of a reliable biomarker.

For people with albinism, who produce little or no melanin and carry a significantly elevated lifetime risk of UV-related skin damage, the gap between a benign pigmented lesion and an early-stage melanoma is one that clinicians must cross carefully. A protein marker that sharpens that distinction at the cellular level could reduce both missed diagnoses and unnecessary procedures.

The research did not address albinism directly. But the underlying problem it targets — how to read a suspicious lesion accurately — sits at the centre of dermatological care for people with albinism in every region where specialist access is limited.

The journal study did not detail clinical thresholds or treatment implications in the sections available. Those questions remain part of the ongoing research agenda.